What are the differences between somatic and germline BRCA mutations, and how should testing and management be approached in a patient with a BRCA‑associated cancer?

Somatic vs. Germline BRCA Mutations: Testing and Management

Always perform germline BRCA testing first at diagnosis, and only proceed to somatic tumor testing if germline results are negative—never reverse this sequence, as somatic testing alone will miss up to 5% of germline mutations with critical implications for family members. 1, 2

Key Biological Differences

Germline BRCA mutations:

• Present in all cells from birth (inherited) 1
• Found in 13-15% of women with epithelial ovarian cancer 1, 2
• Confer hereditary cancer risk to family members requiring cascade testing 1
• Predict lifetime risks of breast, ovarian, pancreatic, and prostate cancers 1

Somatic BRCA mutations:

• Acquired only in tumor tissue during oncogenesis 1
• Found in an additional 5-7% of ovarian cancer patients beyond germline carriers 1, 2
• Have no implications for family members 1
• Provide therapeutic targets but no hereditary risk 1

Testing Algorithm for Cancer Patients

Step 1: Germline Testing at Diagnosis

• Perform germline sequencing immediately upon cancer diagnosis to enable treatment decisions and identify family risk 1, 2
• Use a multigene panel including at minimum: BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, MLH1, MSH2, MSH6, PMS2, and PALB2 1
• Panel testing costs are comparable to BRCA1/2-only testing, making comprehensive panels the practical choice 1
• Germline DNA sequencing is the most sensitive approach and must precede somatic testing 1, 2

Step 2: Somatic Testing Only If Germline Negative

• If germline testing is negative for BRCA mutations, then sequence tumor tissue to detect somatic BRCA mutations in an additional 5% of patients 1
• Somatic testing should be offered to women without germline pathogenic BRCA1/2 variants, as results guide therapeutic decisions 1
• For women who completed upfront therapy and are in observation, somatic testing may be deferred until recurrence 1

Critical Pitfall to Avoid

Never use tumor-only sequencing or somatic results to decide whether germline testing is needed 1, 2. This approach:

• Misses germline mutations in up to 5% of cases due to lower sensitivity of somatic testing 1
• Falsely reassures family members who may carry hereditary mutations 1
• Has "grave implications" for relatives who remain unaware of their cancer risk 1

Tumor-normal paired sequencing definitively distinguishes somatic from germline variants, but tumor-only sequencing cannot reliably make this distinction 1, 3. Bioinformatic inference from tumor data alone is imperfect and may discard true somatic alterations or miss genuine germline variants 1, 3.

Management Based on Mutation Type

For Germline BRCA Mutations

Therapeutic implications:

• Patients with advanced cancer and germline BRCA mutations are eligible for PARP inhibitor maintenance therapy (e.g., olaparib) after response to initial platinum-based chemotherapy 1
• Germline BRCA1/2 defects predict sensitivity to platinum salts and PARP inhibitors 1, 3

Family cascade testing:

• Presence of a germline mutation at any cancer stage mandates discussions with family members to evaluate their cancer risks 1
• First- and second-degree relatives should be offered genetic counseling and testing 1
• Risk-reducing salpingo-oophorectomy should be considered for carriers of BRCA1/2 and related Fanconi genes (RAD51C, RAD51D, BRIP1) per NCCN guidelines 1

Surveillance and prevention:

• Enhanced cancer screening protocols for mutation carriers 2
• Risk-reducing surgeries are the evidence-based approach, as screening does not reduce mortality in high-risk individuals 2

For Somatic BRCA Mutations

Therapeutic implications:

• Somatic BRCA mutations also predict sensitivity to PARP inhibitors and platinum-based chemotherapy 1, 3
• In one cohort, 21% of patients with pathogenic variants (germline or somatic) had therapy discussions or initiated targeted treatment within one year 1, 3
• Somatic mutations identified by cfDNA analysis may guide treatment selection in metastatic disease 4

No family implications:

• Somatic mutations are not inherited and do not require cascade testing of relatives 1
• Genetic counseling focuses solely on the patient's treatment options 1

Repeat testing considerations:

• Repeat tumor testing after progression on PARP inhibitors has not shown utility for therapeutic decision-making 1
• Secondary BRCA mutations conferring resistance cannot be used to deny PARP inhibitor therapy in PARP-naïve patients 1

Genetic Counseling Requirements

• Provide pre- and post-test genetic counseling to all patients undergoing testing 1
• Discuss benefits, risks, limitations, probability of finding a mutation, and implications for patient and family 1
• Address how results influence medical management including surveillance and risk-reducing surgeries 2
• Explain the Genetic Information Nondiscrimination Act protections against genetic discrimination in health insurance and employment 1
• Acknowledge patient feelings of worry, anxiety, guilt, and fear about results and financial strain 1

Histology-Specific Considerations

• High-grade serous ovarian cancer has the highest BRCA mutation frequency, but genetic testing should not be restricted to this histology 1
• Endometrioid, clear cell, low-grade serous, and carcinosarcoma subtypes have BRCA mutation risks approaching 28% 1
• Mucinous ovarian cancers are least likely to harbor germline BRCA mutations but may have mismatch repair defects in up to 20% of cases 1

Variants of Uncertain Significance (VUS)

• VUS should not drive routine clinical decisions outside of highly controlled clinical trials at academic centers 3
• Testing laboratories must report reclassifications of VUS to pathogenic/likely pathogenic or benign/likely benign 1
• Physicians should share variant results and refer patients to clinical research on variant classification when available 1
• Reclassification is an ongoing process, and variants may eventually be definitively classified 1

Health Disparities in Testing

• Only 34% of non-Hispanic white women, 22% of Black women, and 24% of Hispanic women with ovarian cancer receive genetic testing 1
• Clinicians must actively address barriers to testing access across all patient populations 1
• Only one-third of all women diagnosed with ovarian cancer undergo genetic testing despite guideline recommendations 1